ELSEVIER

Clinica Chimica Acta 272 (1998) 235–236

Author index

Volume 272 (1998)

Aly, O., see Hermans, C. **272**, 101
Andrade, A., see Páramo, C. **272**, 231
Apple, F.S., see Henderson, A.R. **272**, 93
Apple, F.S., Sharkey, S.W., Falahati, A., Murakami, M., Mitha, N., Christensen, D., Assessment of left ventricular function using serum cardiac troponin I measurements following myocardial infarction **272**, 59

Bachmann, C., see Boulat, O. **272**, 127
Bais, R., see Foo, A.Y. **272**, 137
Basharova, L.A., see Golovanova, N.K. **272**, 197
Berg, K.J., Kristoffersen, D.T., Djøseland, O., Hartmann, A., Breistein, E., Lund, K.K., Narverud, J., Nossen, J.Ø., Stenstrøm, J., Reference range of some enzymes and proteins in untimed overnight urine and their stability after freezing **272**, 225
Bergelson, L.D., see Golovanova, N.K. **272**, 197
Bernard, A., see Hermans, C. **272**, 101
Boulat, O., Krieg, M.A., Janin, B., Burckhardt, P., Francioli, P., Bachmann, C., Clinical chemistry variables in normal elderly and healthy ambulatory populations: comparison with reference values **272**, 127
Breistein, E., see Berg, K.J. **272**, 225
Burckhardt, P., see Boulat, O. **272**, 127

Chapman, R.S., see Rees, G.S. **272**, 149
Cheung, C., see Keating, J. **272**, 159
Christensen, D., see Apple, F.S. **272**, 59

DeJongste, M.J.L., see Swaanenburg, J.C.J.M. **272**, 171
Demailly, S., see Mesli, S. **272**, 183
Derache, P., see Mesli, S. **272**, 183
Djøseland, O., see Berg, K.J. **272**, 225

Engel, I., see Siggelkow, H. **272**, 111

Falahati, A., see Apple, F.S. **272**, 59
Foo, A.Y., Bais, R., Amylase measurement with 2-chloro-4-nitrophenyl maltotrioside as substrate **272**, 137
Francioli, P., see Boulat, O. **272**, 127

García-Mayor, R.V., see Páramo, C. **272**, 231
Gerhardt, W., see Henderson, A.R. **272**, 93
Gerhardt, W., Ljungdahl, L., Troponin T: A sensitive and specific diagnostic and prognostic marker of myocardial damage **272**, 47
Glatz, J.F.C., van der Vusse, G.J., Simoons, M.L., Kragten, J.A., van Dieijen-Visser, M.P., Hermens, W.T., Fatty acid-binding protein and the early detection of acute myocardial infarction **272**, 87
Glatz, J.F.C., see Wodzig, K.W.H. **272**, 209
Golovanova, N.K., Gracheva, E.V., Basharova, L.A., Kozlov, S.G., Lyakishev, A.A., Prokazova, N.V., Bergelson, L.D., Autoantibodies to gangliosides in sera of atherosclerotic patients **272**, 197
Górski, J., see Wodzig, K.W.H. **272**, 209
Gracheva, E.V., see Golovanova, N.K. **272**, 197

Hartmann, A., see Berg, K.J. **272**, 225
Henderson, A.R., The use of biochemical markers in ischaemic heart disease: Prefactory remarks **272**, 3
Henderson, A.R., Gerhardt, W., Apple, F.S., The use of biochemical markers in ischaemic heart disease: summary of the roundtable and extrapolations **272**, 93
Hermans, C., Aly, O., Nyberg, B.-I., Peterson, C., Bernard, A., Determinants of Clara cell protein

0009-8981/98/$19.00 Elsevier Science B.V. All rights reserved
PII S009-8981(98)00054-0

(CC16) concentration in serum: a reassessment with two different immunoassays **272**, 101
Hermens, W.T., see Glatz, J.F.C. **272**, 87
Hermens, W.Th., see Wodzig, K.W.H. **272**, 209
Hilmes, D., see Siggelkow, H. **272**, 111
Hüfner, M., see Siggelkow, H. **272**, 111

Janin, B., see Boulat, O. **272**, 127
Jouzier, E., see Mesli, S. **272**, 183

Keating, J., Cheung, C., Peters, T.J., Sherwood, R.A., Carbohydrate deficient transferrin in the assessment of alcohol misuse: Absolute or relative measurements? A comparison of two methods with regard to total transferrin concentration **272**, 159
Klaase, J.M., see Swaanenburg, J.C.J.M. **272**, 171
Kozlov, S.G., see Golovanova, N.K. **272**, 197
Kragten, J.A., see Glatz, J.F.C. **272**, 87
Kragten, J.A., see Wodzig, K.W.H. **272**, 209
Krieg, M.A., see Boulat, O. **272**, 127
Kristoffersen, D.T., see Berg, K.J. **272**, 225
Kurre, W., see Siggelkow, H. **272**, 111

Le Moigne, F., see Mesli, S. **272**, 183
Legon, S., see Rees, G.S. **272**, 149
Ljungdahl, L., see Gerhardt, W. **272**, 47
Lund, K.K., see Berg, K.J. **272**, 225
Lyakishev, A.A., see Golovanova, N.K. **272**, 197

Mair, J., Glycogen phosphorylase isoenzyme BB to diagnose ischaemic myocardial damage **272**, 79
Mesli, S., Demailly, S., Le Moigne, F., Derache, P., Jouzier, E., Evaluation of the new automated ELISA Vidas® Lp(a) assay. Comparison with an immunonephelemetric method **272**, 183
Mitha, N., see Apple, F.S. **272**, 59
Modrzejewski, W., see Wodzig, K.W.H. **272**, 209
Murakami, M., see Apple, F.S. **272**, 59

Narverud, J., see Berg, K.J. **272**, 225
Nicholl, C.G., see Rees, G.S. **272**, 149
Nossen, J.Ø., see Berg, K.J. **272**, 225
Nyberg, B.-I., see Hermans, C. **272**, 101

Panteghini, M., Diagnostic application of CK-MB mass determination **272**, 23
Páramo, C., Pérez Mendez, L.F., Andrade, A., García-Mayor, R.V., Short Synacthen test: standard versus low dose in the evaluation of patients with pituitary diseases **272**, 231
Pérez Mendez, L.F., see Páramo, C. **272**, 231
Peters, T.J., see Keating, J. **272**, 159
Peterson, C., see Hermans, C. **272**, 101
Plebani, M., Zaninotto, M., Diagnostic strategies using myoglobin measurement in myocardial infarction **272**, 69
Prokazova, N.V., see Golovanova, N.K. **272**, 197

Rebenstorff, K., see Siggelkow, H. **272**, 111
Rees, G.S., Symes, E.K., Nicholl, C.G., Legon, S., Chapman, R.S., Lack of correlation of free deoxypyridinoline excretion with Taq1 restriction length polymorphisms in the vitamin D receptor gene in males **272**, 149
Roberts, R., Early diagnosis of myocardial infarction with MB CK isoforms **272**, 33

Sharkey, S.W., see Apple, F.S. **272**, 59
Sherwood, R.A., see Keating, J. **272**, 159
Siggelkow, H., Hilmes, D., Rebenstorff, K., Kurre, W., Engel, I., Hüfner, M., Analysis of human primary bone cells by fluorescence activated cell scanning: methodological problems and preliminary results **272**, 111
Simoons, M.L., see Glatz, J.F.C. **272**, 87
Stenstrøm, J., see Berg, K.J. **272**, 225
Swaanenburg, J.C.J.M., Klaase, J.M., DeJongste, M.J.L., Zimmerman, K.W., Ten Duis, H.J., Troponin I, troponin T, CKMB-activity and CKMB-mass as markers for the detection of myocardial contusion in patients who experienced blunt trauma **272**, 171
Symes, E.K., see Rees, G.S. **272**, 149

ten Duis, H.J., see Swaanenburg, J.C.J.M. **272**, 171

van der Vusse, G.J., see Glatz, J.F.C. **272**, 87
van Dieijen-Visser, M.P., see Glatz, J.F.C. **272**, 87
van Dieijen-Visser, M.P., see Wodzig, K.W.H. **272**, 209

Wodzig, K.W.H., Kragten, J.A., Modrzejewski, W., Górski, J., van Dieijen-Visser, M.P., Glatz, J.F.C., Hermens, W.Th., Thrombolytic therapy does not change the release ratios of enzymatic and non-enzymatic myocardial marker proteins **272**, 209
Wu, A.H.B., Analytical and clinical evaluation of new diagnostic tests for myocardial damage **272**, 11

Zaninotto, M., see Plebani, M. **272**, 69
Zimmerman, K.W., see Swaanenburg, J.C.J.M. **272**, 171

ELSEVIER

Clinica Chimica Acta 272 (1998) 237–241

Subject index

Volume 272 (1998)

Acute coronary syndrome; Diagnostic, prognostic marker; Diagnostic strategy; Minor myocardial damage; MMD; Myocardial damage; Myocardial infarction; Renal failure; Troponin T; Troponin I **272**, 47

Acute coronary syndromes; Troponin T; Troponin I; CK-MB; Myoglobin; Stable angina; Unstable angina; Minor myocardial damage; Myocardial infarction; Diagnosis; Prognosis **272**, 93

Acute myocardial infarction; Creatine kinase (EC 2.7.3.2) MB isoenzyme; Cardiac troponin T and I; Brain natriuretic peptide; Unstable angina risk stratification; Immunoassays; Point-of-care testing **272**, 11

Acute myocardial infarction; Diagnostic strategies; Skeletal muscle damage; Thrombolysis; Troponin I **272**, 69

Acute myocardial infarction; Fatty-acid binding; Early detection **272**, 87

Acute myocardial infarction; Glycogen phosphorylase; Ischaemic myocardial damage; Isoenzyme BB; Unstable angina **272**, 79

Alcohol misuse; Transferrin; Viral hepatitis; Ion-exchange chromatography **272**, 159

Ambulatory population; Reference values; Clinical Chemistry variables; Elderly population **272**, 127

Assay; Lipoprotein (a) **272**, 183

Atherosclerosis; Serotonin; Ganglioside GM3; Autoantibodies **272**, 197

Autoantibodies; Atherosclerosis; Serotonin; Ganglioside GM3 **272**, 197

Blunt trauma; Myocardial contusion; Troponin I; Troponin T **272**, 171

Body mass index; Clara cell protein (CC16–CC10–CCSP); Lung marker; Smoking; Lipids; Latex immunoassay; Fluorescence enzyme immunoassay **272**, 101

Bone alkaline phosphatase; Human osteoblast-like cells; Human osteosarcoma cell line; Fluorescence activated cell scanning (FACS); Collagen/procollagen I **272**, 111

Bone resorption; Vitamin D receptor alleles; Urinary free deoxypyridinoline **272**, 149

Brain natriuretic peptide; Acute myocardial infarction; Creatine kinase (EC 2.7.3.2) MB isoenzyme; Cardiac troponin T and I; Unstable angina risk stratification; Immunoassays; Point-of-care testing **272**, 11

Cardiac troponin I; Myocardial infarct; Serum **272**, 59

Cardiac troponin T and I; Acute myocardial infarction; Creatine kinase (EC 2.7.3.2) MB isoenzyme; Brain natriuretic peptide; Unstable angina risk stratification; Immunoassays; Point-of-care testing **272**, 11

0009-8981/98/$19.00 Elsevier Science B.V. All rights reserved
PII S009-8981(98)00055-2

2-chloro-4-nitrophenyl maltotrioside (CNP-G3); Measurement of amylase activity; Method comparison **272**, 137

CK-MB; Troponin T; Troponin I; Myoglobin; Acute coronary syndromes; Stable angina; Unstable angina; Minor myocardial damage; Myocardial infarction; Diagnosis; Prognosis **272**, 93

Clara cell protein (CC16–CC10–CCSP); Lung marker; Smoking; Body mass index; Lipids; Latex immunoassay; Fluorescence enzyme immunoassay **272**, 101

Clinical Chemistry variables; Reference values; Elderly population; Ambulatory population **272**, 127

Collagen/procollagen I; Human osteoblast-like cells; Human osteosarcoma cell line; Fluorescence activated cell scanning (FACS); Bone alkaline phosphatase **272**, 111

Creatine kinase; Fatty acid-binding protein; Myoglobin; Lactate dehydrogenase; Infarct size **272**, 209

Creatine kinase (EC 2.7.3.2) MB isoenzyme; Acute myocardial infarction; Cardiac troponin T and I; Brain natriuretic peptide; Unstable angina risk stratification; Immunoassays; Point-of-care testing **272**, 11

Diagnosis; Myocardial infarction; Musculoskeletal diseases; Laboratory; Sensitivity and specificity **272**, 23

Diagnosis; Troponin T; Troponin I; CK-MB; Myoglobin; Acute coronary syndromes; Stable angina; Unstable angina; Minor myocardial damage; Myocardial infarction; Prognosis **272**, 93

Diagnostic MI marker; MB CK isoforms; Myocardial infarction; Troponin T **272**, 33

Diagnostic strategies; Acute myocardial infarction; Skeletal muscle damage; Thrombolysis; Troponin I **272**, 69

Diagnostic strategy; Acute coronary syndrome; Diagnostic, prognostic marker; Minor myocardial damage; MMD; Myocardial damage; Myocardial infarction; Renal failure; Troponin T; Troponin I **272**, 47

Diagnostic, prognostic marker; Acute coronary syndrome; Diagnostic strategy; Minor myocardial damage; MMD; Myocardial damage; Myocardial infarction; Renal failure; Troponin T; Troponin I **272**, 47

Early detection; Fatty-acid binding; Acute myocardial infarction **272**, 87

Elderly population; Reference values; Clinical Chemistry variables; Ambulatory population **272**, 127

Enzymes; Urine; Proteins; Storage; Normal values **272**, 225

Fatty-acid binding; Acute myocardial infarction; Early detection **272**, 87

Fatty acid-binding protein; Myoglobin; Creatine kinase; Lactate dehydrogenase; Infarct size **272**, 209

Fluorescence activated cell scanning (FACS); Human osteoblast-like cells; Human osteosarcoma cell line; Bone alkaline phosphatase; Collagen/procollagen I **272**, 111

Fluorescence enzyme immunoassay; Clara cell protein (CC16–CC10–CCSP); Lung marker; Smoking; Body mass index; Lipids; Latex immunoassay **272**, 101

Ganglioside GM3; Atherosclerosis; Serotonin; Autoantibodies **272**, 197

Glycogen phosphorylase; Acute myocardial infarction; Ischaemic myocardial damage; Isoenzyme BB; Unstable angina **272**, 79

Human osteoblast-like cells; Human osteosarcoma cell line; Fluorescence activated cell scanning (FACS); Bone alkaline phosphatase; Collagen/procollagen I **272**, 111

Human osteosarcoma cell line; Human osteoblast-like cells; Fluorescence activated cell scanning (FACS); Bone alkaline phosphatase; Collagen/procollagen I **272**, 111

Hypothalamic–pituitary–adrenal axis; Synacthen test; Pituitary diseases **272**, 231

Immunoassays; Acute myocardial infarction; Creatine kinase (EC 2.7.3.2) MB isoenzyme;

Cardiac troponin T and I; Brain natriuretic peptide; Unstable angina risk stratification; Point-of-care testing **272**, 11

Infarct size; Fatty acid-binding protein; Myoglobin; Creatine kinase; Lactate dehydrogenase **272**, 209

Ion-exchange chromatography; Alcohol misuse; Transferrin; Viral hepatitis **272**, 159

Ischaemic myocardial damage; Acute myocardial infarction; Glycogen phosphorylase; Isoenzyme BB; Unstable angina **272**, 79

Isoenzyme BB; Acute myocardial infarction; Glycogen phosphorylase; Ischaemic myocardial damage; Unstable angina **272**, 79

Laboratory; Myocardial infarction; Musculoskeletal diseases; Diagnosis; Sensitivity and specificity **272**, 23

Lactate dehydrogenase; Fatty acid-binding protein; Myoglobin; Creatine kinase; Infarct size **272**, 209

Latex immunoassay; Clara cell protein (CC16–CC10–CCSP); Lung marker; Smoking; Body mass index; Lipids; Fluorescence enzyme immunoassay **272**, 101

Lipids; Clara cell protein (CC16–CC10–CCSP); Lung marker; Smoking; Body mass index; Latex immunoassay; Fluorescence enzyme immunoassay **272**, 101

Lipoprotein (a); Assay **272**, 183

Lung marker; Clara cell protein (CC16–CC10–CCSP); Smoking; Body mass index; Lipids; Latex immunoassay; Fluorescence enzyme immunoassay **272**, 101

Markers of myocardial damage; Myocardial infarction; Prognosis; Sensitivity; Specificity; Test assessment **272**, 3

MB CK isoforms; Myocardial infarction; Troponin T; Diagnostic MI marker **272**, 33

Measurement of amylase activity; Method comparison; 2-chloro-4-nitrophenyl maltotrioside (CNP-G3) **272**, 137

Method comparison; Measurement of amylase activity; 2-chloro-4-nitrophenyl maltotrioside (CNP-G3) **272**, 137

Minor myocardial damage; Acute coronary syndrome; Diagnostic, prognostic marker; Diagnostic strategy; MMD; Myocardial damage; Myocardial infarction; Renal failure; Troponin T; Troponin I **272**, 47

Minor myocardial damage; Troponin T; Troponin I; CK-MB; Myoglobin; Acute coronary syndromes; Stable angina; Unstable angina; Myocardial infarction; Diagnosis; Prognosis **272**, 93

MMD; Acute coronary syndrome; Diagnostic, prognostic marker; Diagnostic strategy; Minor myocardial damage; Myocardial damage; Myocardial infarction; Renal failure; Troponin T; Troponin I **272**, 47

Musculoskeletal diseases; Myocardial infarction; Diagnosis; Laboratory; Sensitivity and specificity **272**, 23

Myocardial contusion; Blunt trauma; Troponin I; Troponin T **272**, 171

Myocardial damage; Acute coronary syndrome; Diagnostic, prognostic marker; Diagnostic strategy; Minor myocardial damage; MMD; Myocardial infarction; Renal failure; Troponin T; Troponin I **272**, 47

Myocardial infarct; Cardiac troponin I; Serum **272**, 59

Myocardial infarction; Acute coronary syndrome; Diagnostic, prognostic marker; Diagnostic strategy; Minor myocardial damage; MMD; Myocardial damage; Renal failure; Troponin T; Troponin I **272**, 47

Myocardial infarction; Markers of myocardial damage; Prognosis; Sensitivity; Specificity; Test assessment **272**, 3

Myocardial infarction; MB CK isoforms; Troponin T; Diagnostic MI marker **272**, 33

Myocardial infarction; Musculoskeletal diseases; Diagnosis; Laboratory; Sensitivity and specificity **272**, 23

Myocardial infarction; Troponin T; Troponin I; CK-MB; Myoglobin; Acute coronary syndromes; Stable angina; Unstable angina; Minor myocardial damage; Diagnosis; Prognosis **272**, 93

Myoglobin; Fatty acid-binding protein; Creatine kinase; Lactate dehydrogenase; Infarct size **272**, 209

Myoglobin; Troponin T; Troponin I; CK-MB; Acute coronary syndromes; Stable angina; Unstable angina; Minor myocardial damage; Myocardial infarction; Diagnosis; Prognosis **272**, 93

Normal values; Urine; Enzymes; Proteins; Storage **272**, 225

Pituitary diseases; Hypothalamic–pituitary–adrenal axis; Synacthen test **272**, 231

Point-of-care testing; Acute myocardial infarction; Creatine kinase (EC 2.7.3.2) MB isoenzyme; Cardiac troponin T and I; Brain natriuretic peptide; Unstable angina risk stratification; Immunoassays **272**, 11

Prognosis; Markers of myocardial damage; Myocardial infarction; Sensitivity; Specificity; Test assessment **272**, 3

Prognosis; Troponin T; Troponin I; CK-MB; Myoglobin; Acute coronary syndromes; Stable angina; Unstable angina; Minor myocardial damage; Myocardial infarction; Diagnosis **272**, 93

Proteins; Urine; Enzymes; Storage; Normal values **272**, 225

Reference values; Clinical Chemistry variables; Elderly population; Ambulatory population **272**, 127

Renal failure; Acute coronary syndrome; Diagnostic, prognostic marker; Diagnostic strategy; Minor myocardial damage; MMD; Myocardial damage; Myocardial infarction; Troponin T; Troponin I **272**, 47

Sensitivity; Markers of myocardial damage; Myocardial infarction; Prognosis; Specificity; Test assessment **272**, 3

Sensitivity and specificity; Myocardial infarction; Musculoskeletal diseases; Diagnosis; Laboratory **272**, 23

Serotonin; Atherosclerosis; Ganglioside GM3; Autoantibodies **272**, 197

Serum; Myocardial infarct; Cardiac troponin I **272**, 59

Skeletal muscle damage; Acute myocardial infarction; Diagnostic strategies; Thrombolysis; Troponin I **272**, 69

Smoking; Clara cell protein (CC16–CC10–CCSP); Lung marker; Body mass index; Lipids; Latex immunoassay; Fluorescence enzyme immunoassay **272**, 101

Specificity; Markers of myocardial damage; Myocardial infarction; Prognosis; Sensitivity; Test assessment **272**, 3

Stable angina; Troponin T; Troponin I; CK-MB; Myoglobin; Acute coronary syndromes; Unstable angina; Minor myocardial damage; Myocardial infarction; Diagnosis; Prognosis **272**, 93

Storage; Urine; Enzymes; Proteins; Normal values **272**, 225

Synacthen test; Hypothalamic–pituitary–adrenal axis; Pituitary diseases **272**, 231

Test assessment; Markers of myocardial damage; Myocardial infarction; Prognosis; Sensitivity; Specificity **272**, 3

Thrombolysis; Acute myocardial infarction; Diagnostic strategies; Skeletal muscle damage; Troponin I **272**, 69

Transferrin; Alcohol misuse; Viral hepatitis; Ion-exchange chromatography **272**, 159

Troponin I; Acute coronary syndrome; Diagnostic, prognostic marker; Diagnostic strategy; Minor myocardial damage; MMD; Myocardial damage; Myocardial infarction; Renal failure; Troponin T **272**, 47

Troponin I; Acute myocardial infarction; Diagnostic strategies; Skeletal muscle damage; Thrombolysis **272**, 69

Troponin I; Myocardial contusion; Blunt trauma; Troponin T **272**, 171

Troponin I; Troponin T; CK-MB; Myoglobin; Acute coronary syndromes; Stable angina; Un-

stable angina; Minor myocardial damage; Myocardial infarction; Diagnosis; Prognosis **272**, 93

Troponin T; Acute coronary syndrome; Diagnostic, prognostic marker; Diagnostic strategy; Minor myocardial damage; MMD; Myocardial damage; Myocardial infarction; Renal failure; Troponin I **272**, 47

Troponin T; MB CK isoforms; Myocardial infarction; Diagnostic MI marker **272**, 33

Troponin T; Myocardial contusion; Blunt trauma; Troponin I **272**, 171

Troponin T; Troponin I; CK-MB; Myoglobin; Acute coronary syndromes; Stable angina; Unstable angina; Minor myocardial damage; Myocardial infarction; Diagnosis; Prognosis **272**, 93

Unstable angina; Acute myocardial infarction; Glycogen phosphorylase; Ischaemic myocardial damage; Isoenzyme BB **272**, 79

Unstable angina; Troponin T; Troponin I; CK-MB; Myoglobin; Acute coronary syndromes; Stable angina; Minor myocardial damage; Myocardial infarction; Diagnosis; Prognosis **272**, 93

Unstable angina risk stratification; Acute myocardial infarction; Creatine kinase (EC 2.7.3.2) MB isoenzyme; Cardiac troponin T and I; Brain natriuretic peptide; Immunoassays; Point-of-care testing **272**, 11

Urinary free deoxypyridinoline; Vitamin D receptor alleles; Bone resorption **272**, 149

Urine; Enzymes; Proteins; Storage; Normal values **272**, 225

Viral hepatitis; Alcohol misuse; Transferrin; Ion-exchange chromatography **272**, 159

Vitamin D receptor alleles; Bone resorption; Urinary free deoxypyridinoline **272**, 149